Actividad de los macrólidos sobre Haemophilus influenzae: Una revisión crítica

Medicina Clinica

Volumn 110, Issue SUPPL. 1, 1998, Pages 60-64

  Perea, Evelio J ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; MACROLIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CLARITHROMYCIN; ERYTHROMYCIN; MIOKAMYCIN; ROXITHROMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; DRUG EFFECT; HAEMOPHILUS INFLUENZAE; HUMAN; MICROBIOLOGICAL EXAMINATION; REVIEW; ANTIBACTERIAL ACTIVITY; BACTERIOSTASIS; CLINICAL TRIAL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OTORHINOLARYNGOLOGY; PH; RESPIRATORY TRACT INFECTION; SINUSITIS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS;

EID: 0031915328     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Goldstein FW, Emirian MF, Coutrot A, Acar JF. Bacteriostatic and bactericidal activity of azythromycin against Haemophilus influenzae. J Antimicrob Chemother 1990; 25 (Supl A): 25-28.
2. Soriano F. Actividad in vitro e in vivo de los antibióticos macrólidos frente a Haemophilus influenzae. Rev Esp Quimioterap 1991; 4: 281-285.
3. NCCLS National Committee for Clinical Laboratory Standards. Methods for cilution antimicrobial susceptibility for bacteria that grow aerobically. Approved Standard M7-A2, NCCLS. Villanova, Pa NCCLS, 1991; 11: 17
4. NCCLS. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Suplemento 100-S6. Villanova, PA: NCCLS, 1995; 15: 14.
5. NCCLS. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. Villanova, Pa, NCCLS; 1997.
6. Doern GV. In vitro susceptibility testing of Haemophilus influenzae: review of new National Committee for Clinical Laboratory Standards recom mendations. J Clin Microbiol 1992; 30: 3.035-3.038.
7. Perea EJ. Problemas en el estudio de la sensibilidad de Haemophilus Influenzae. Enferm Infecc Microbiol Clin 1993; 11: 45-50
8. Soriano F, Fernández-Robles R. Criterios de susceptibilidad. Antibóticos macrólidos: S. pneumonias y H. influenzae. Enferm Infecc Microbiol Clin 1996; 14: 503-504.
9. Courvalin P, Soussy C-J. Report of the Comité de l'Antibiogramme de la Société Française de Microbiologie. Clin Microbiol Infect 1996; 2 (Supl): 1-49.
10. Needham CA. Haemophilus influenzas antibiotic susceptibility. Clin Microbiol Rev 1988; 1: 218-227.
11. Barry AL, Fernandes PB, Jorgensen JH, Thornsberry C, Hardy DJ, Jones RN Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test J Clin Microbiol 1988; 26: 2.415-2.420.
12. Fernandes PB, Hardy D, Bailer R, McDonald E, Pintar J, Ramer N et al. Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. Antimicrob Agents Chemother 1987; 31: 1.243-1.250.
13. Nilius AM, Beyer JM, Flamen RK, Tanaka SK. Variability in susceptibilities of Haemophilus influenzae to claritromycin and azithromycin due to medium pH. J Clin Microbiol 1997; 35: 1.311-1.315.
14. Barza M, Eisenberg E. Clarithromycin and azithromycin. Infect Dis Clin 1996; 5: 291-302.
15. Drusano GL, Goldstein FW. Relevance of the Alexander project: pharmacodynamic considerations. J Antimicrob Chemother 1996; 38 (Supl A): 141-154.
16. Capobianco JO, Goldman RC. A concurrent study of macrolide transport, binding to ribosomes and inhibition of protein synthesis n Haemophilus influenzae. Recent Res Devel Antimicrob Agents Chemother 1996; 1: 95-102.
17. Dabernat H, Delmas C, Seguy M, Fourtillan JB, Girault J, Lareng MB. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in vitro and serum bactericidal tests. J Antimicrob Chemother 1991; 27 (Supl A): 19-30.
18. Olsson-Liljequist B, Huffman BM. In vitro activity of clarithromycin combined with its 14-hydroxy metabolite A62671 against Haemophilus influenzae. J Antimicrob Chemother 1991; 27 (Supl A): 11-17.
19. Hardy DJ, Swanson RA, Rode RN, Kavsh K, Shiprowitz NL, Clement JJ. Enhancement of the in vitro and in vivo activities of clarithromycin against H. influenzae by 14-hydroxy-clarithromycin its major metabolite in humans. Antimicrob Agents Chemother 1990; 34: 1.407-1.413.
20. Brown S, Barry AL, Burton P. Susceptibility surveillance of US respiratory pathogen isolates to newer macrolide and azalide antibiotics. Intern J Antimicrob Agents 1996; 7: 53-58.
21. Rodríguez-Avial C, Picazo JJ. Resistencia de H. influenzae. Repercusión terapéutica: Antibióticos convencionales y nuevas opciones. Rev Esp Quimioterap 1991; 4: 277-279.
22. Comité de l'Antibiogramme de la Société Française de Microbiologie. Communiqué 1995. Path Biol 1995; 43: 1-8.
23. Working Party of the British Society for Antimicrobial Chemotherapy. A guide to sensitivity testing. J Antimicrob Chemother 1991; 27 (Supl D): 1-50.
24. Baquero F, Martínez Beltrán J, Cantón J et al (Mensura). Definition and determination of in vitro antibiotic susceptibility breakpoint for bacteria in Spain. MIC. En prensa.
25. Ellner PD, Neu HC. The inhibitory quotient. JAMA 1981; 246: 1.575-1.578.
26. a ed.). Nueva York MacMillan, 1995: 1.080-1.085.
27. Pascual A, Conejo HC, Garcia I, Perea EJ. Factors affecting the intracellular accumulation and activity of azithromycin. J Antimicrob Chemother 1995; 35: 85-93.
28. Pascual A, Uptake and intracellular activity of antimicrobial agents in phagocytic cells. Rev Med Microbiol 1995; 6: 228-235.
29. Retsema JA, Girard AE, Girard D, Millisen WB. Relationship of high tissue concentrations of azithromycin to bacteric:dal activity and efficacy in vivo. J Antimicrob Chemother 1990; 25 (Supl A): 83-89.
30. Maskell JP, Sefton AM, Williams JD: Comparative in vitro activity of azithromycin and erithromycin against gram positive cocci, H. influenzae and anaerobes. J Antimicrob Chemother 1990; 25 (Supl A): 19-24.
31. Eisenberg E, Barza M. Azithromycin and clarithromycin. Curr Clin Top Infect Dis 1994; 14: 52-79.
32. Karma P, Pukander J, Penttila M, Ylikoski J, Savolainen S, Olen L et al. The comparative efficacy and safety of clarilhromycin and amoxicillin in the treatment of outpaints with acute maxillary sinusitis. J Antimicrob Chemother 1990; 27: (Supl): 83-90.
33. Casiano P. Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Am J Med 1991; 25 (Supl): 27-30.
34. Dubois J, St. Pierre C, Tremblay C. Efficacy of clarithromycin vs. amoxacillin/clavulanate in the treatment of acute maxillary sinusitis. Ear Nose Throat J 1993; 72: 804-810.
35. Pukander J, Jero J, Kaprio E, Sorri M. Clarthromycin vs. amoxacillin suspensions in the treatment of pediatric patients with acute otitis media. Pediatr Infect Dis J 1993; 12 (Supl): 118-121.
36. McCarly J, Phillips A, Wilsanen R. Comparative safety and efficacy of clarithromycin and amoxicillin/clavulanate in the treatment of acute otitis media in children. Pediatr Infect Dis J 1993; 12 (Supl): 122-127.
37. Gooch W, Gan V, Corder W, Khurana C, Andrews W. Clarithromycin and cefaclor suspensions in the treatment of acute otitis media in children. Pediatr Infect Dis J 1993; 12 (Supl): 128-133.
38. Pozzi E, Grossi E, Pecori A. Azithromycin vs. clarithromycin in the treatment of acute exacerbations of chronic bronchitis. Curr Ther Res Clin Exp 1994; 55: 759-764.
39. Aldons P. A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother 1991; 27 (Supl): 101-108.
40. Wettengel R. Comparison of clarithromycin and cefaclor in the treatment of mild o moderate bronchitis. Santa Fe (NM): Proceedings and abstracts of the First International Conference on the Macrolides, Azalides. and Streptogramins, 1992.
41. Dark D. Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections. Am J Med 1991; 91: 531-535.
42. Saint S, Bent S, Vittinghoff E, Graddy D. Antibiotics in chronic obstructive pulmonary disease exacerbations: a Meta-analysis, JAMA 1995; 273: 957-960.
43. Davies B, Maesen F, Gubbelmans R. Azithomycin (CP-62: 993) in acute exacerbations of chronic bronchitis: an open clinical, microbiological and pharmacokinetic study. J Antimicrob Chemother 1989; 23: 743-751.
44. Meters JC, Van Barnevel PW, Asin HR, Ligtroet E, Visser MR, Branger T et al. Double-blind randomized study comparing the efficacies and saleties of a short course (3 days) of azilhromycin and a 5-day course of amoxicillin in patients with acute exacerbation of chronic bronchitis. Antimicrob Agents Chemother 1992; 36: 1.456-4.459.
45. Bachaud RT. Comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1991; 27 (Supl A): 91-100.
46. Dabernat H, Scheinnberg A, Astruc J. Analysis of oral antibiotic treatment that failed to prevent the development of Haemophilus influenzae meningitis: consequences on mortality. J Antimicrob Chemother 1996; 38: 679-689.
47. F.D.A. New Antimicrobial Agents Approved by the US Food and Drug Administration in 1996 and new indications for previously approved agents. Antimicrob Agents Chemother 1997; 41: 878.